Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

BioCT welcomes new member New Haven Promise

New Haven Promise builds a college-going, career, and civic-launch culture throughout the city of New Haven in which students in the public schools aspire to attend...

| By Kelley Gipson

Alexion to expand New Haven footprint

Alexion, AstraZeneca’s Rare Disease group, plans to expand its presence in New Haven with space at the new bioscience tower currently under construction at 101...

| By Kelley Gipson

FDA approves agitation treatment from BioXcel

The FDA has approved a drug from New Haven-based BioXcel Therapeutics for the treatment of agitation associated with schizophrenia or bipolar disorder in adults. The FDA ruled that...

| By Kelley Gipson

Weekly Roundup – April 14, 2022 

View this email in your browser Weekly Roundup – April 14, 2022     Yale recently announced a new innovations initiative: Yale Ventures. The initiative aims to...

| By Kelley Gipson

Career News – April 12, 2022 

View this email in your browser Career News – April 12, 2022  BioCT  Member Engagement Manager The John B. Pierce Laboratory  Electronics/Computer Technician (JB03) Oova  Content...

| By Kelley Gipson

Thetis secures $4.2 million for its Cohn’s therapy

Thetis Pharmaceuticals has secured $4.2 million in non-dilutive financing from The Leona M. and Harry B. Helmsley Charitable Trust. Structured as a program-related investment in...

| By Kelley Gipson

Cara presents data at Kidney Foundation meeting

Cara Therapeutics says that biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients...

| By Kelley Gipson

Rallybio appoints Nash and Liu to Board

Rallybio has appointed Christine Nash, MBA and Hui Liu, Ph.D. to its Board of Directors. “Christine’s commercial and product launch experience in rare diseases and Hui’s industry...

| By Kelley Gipson

Weekly Roundup – April 7, 2022 

View this email in your browser Weekly Roundup – April 7, 2022  Cybrexa Therapeutics co-founder Dr. Ranjit Bindra talks about the story behind his success in the latest...